<DOC>
	<DOCNO>NCT01179919</DOCNO>
	<brief_summary>One three Americans obese . Obese subject may may need high dos anti-flu drug know Tamiflu ( oseltamivir ) . The current study do see FDA approve dose oseltamivir achieve similar concentration obese healthy volunteer compare previously show non-obese volunteer .</brief_summary>
	<brief_title>Pharmacokinetics Oseltamivir Carboxylate In Morbidly Obese Subjects</brief_title>
	<detailed_description>The incidence obesity increase dramatically past two decade United States ( US ) . Twenty-five percent adult Americans classify obese . Obesity associate physiological alteration affect drug clearance volume distribution . Obese subject often exclude phase 1 pharmacokinetic study . As result , drug dosing regimen develop clinical use may appropriate obese population . Use fix dose regimen may result dose obese patient . In contrast adjustment drug dose base total body weight may lead dose obese patient . Oseltamivir phosphate ( Tamiflu® ) antiviral agent currently dose 75 mg daily chemoprophylaxis twice daily treatment influenza adult . Oseltamivir rapidly convert active metabolite , oseltamivir carboxylate esterases . The clearance oseltamivir carboxylate dependent tubular secretion glomerular filtration . Given drug elimination pathway may enhance obese individual , oseltamivir carboxylate plasma exposure may lower obese subject compare normal weight subject . Although specific plasma exposure target oseltamivir carboxylate establish , low oseltamivir carboxylate exposure may predispose obese patient treatment failure increase probability emergence oseltamivir-resistant influenza virus . The current study proposes characterize plasma oseltamivir carboxylate concentration-time profile multiple dose oral oseltamivir cohort healthy morbidly obese subject . The study perform use phase 1 , open-label , multiple dose , pharmacokinetic study design twenty obese adult subject . This pilot study provide pharmacokinetic data may incorporate exist oseltamivir carboxylate population pharmacokinetic model define appropriate dos oseltamivir obese patient .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>male female , 18 50 year age nonsmoking lightsmoking ( ≤5 cigarette per day ) volunteer BMI ≥ 40 kg/m2 female subject childbearing potential either surgically sterilize , use effective method contraception ( diaphragm , cervical cap , condom ) agree abstain sex time prestudy screening , entire study period 1 week follow study period . history significant hypersensitivity reaction oseltamivir history gastric bypass surgical procedure history significant clinical illness require pharmacological management abnormal serum electrolyte complete blood count require clinical workup transaminase ( AST ALT ) &gt; 2.5 x upper limit normal estimate creatinine clearance &lt; 50 mL/min ( CockcroftGault equation ) positive urine pregnancy test ( female ) abnormal electrocardiogram ( ECG ) judge study physician unable tolerate venipuncture multiple blood draw clinically significant abnormal physical examination define physical finding require clinical workup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Oseltamivir</keyword>
	<keyword>Obesity</keyword>
	<keyword>Influenza</keyword>
	<keyword>Pharmacokinetics Obesity</keyword>
</DOC>